Trulicity® and Wegovy® are both glucagon-like peptide-1 (GLP-1) medications, but they use different formulations to target separate conditions. Whether either one is right for you depends on what you’re treating, how your body responds, and what your insurance covers. 

Here’s how Trulicity® and Wegovy® compare on efficacy, side effects, and cost. 

‍

What are the main differences between Trulicity® and Wegovy®?

The primary differences between these two medications are active ingredients and FDA-approved use. Trulicity®’s active ingredient is dulaglutide, and the medicine controls blood sugar and cardiovascular events in people with type 2 diabetes. Wegovy®’s active ingredient is semaglutide, and it helps with weight management.

‍

Here’s how they compare at a glance: 

‍

How do Trulicity® and Wegovy® work?

After you eat, your gut releases GLP-1, a hormone that slows digestion, regulates blood sugar, and tells your brain you’re full. Dulagutide and semaglutide are what doctors call GLP-1 receptor agonists (GLP-1 RAs). This means they bind to GLP-1 receptors and mimic its effects on the body. But the two molecules have different structures, and that changes how each one behaves.

Dulaglutide is a large protein—about 15 times the size of semaglutide—with a built-in protein fragment that slows its breakdown. Your body clears it in roughly five days. Semaglutide is smaller, with a fatty acid chain that latches onto albumin, which is a protein in your blood. That bond keeps semaglutide circulating for about a week. 

Both molecules were originally developed and approved for type 2 diabetes under the brand names Ozempic® and Trulicity®. But in clinical trials, semaglutide consistently produced more weight loss than dulaglutide, likely because it stays active longer and reaches higher sustained levels in the body. These results led semaglutide’s manufacturer, Novo Nordisk, to test semaglutide at a higher dose as a weight loss injection, and the FDA approved it under a new brand name: Wegovy®.

‍

Who should take Trulicity® or Wegovy®?

The choice between these two medications depends mostly on your primary health goal. Here’s an overview of each.

When Trulicity® may fit better

Your doctor may recommend Trulicity® if you’re 10 years old or older with type 2 diabetes and need help lowering your blood sugar alongside diet and exercise. Or, they may suggest this medication if you’re an adult with type 2 diabetes and heart disease or multiple heart disease risk factors.

When Wegovy® may fit better

Your doctor may recommend Wegovy® if you’re an adult or an adolescent 12 or older and:

• Have a BMI of 30 or higher

• Have a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol
• Have heart disease with one of the above BMIs
• Have been diagnosed with MASH, a form of liver disease, with moderate to advanced scarring

Which is more effective for weight loss, Trulicity® or Wegovy®?

Wegovy® produces significantly more weight loss. That’s partly because of how semaglutide behaves in the body, but it’s also because Novo Nordisk calibrated the drug’s dose to help people lose more weight.

Trulicity®'s dose is lower because it targets blood sugar regulation in people with type 2 diabetes. The FDA hasn’t approved using Trulicity® for weight loss. Any weight loss in this medication is a secondary effect of diabetes treatment.

The SUSTAIN 7 trial directly compared the two molecules in 1,201 adults with type 2 diabetes over 40 weeks. Semaglutide (1.0 mg) reduced body weight by about 7%, more than twice the 3% reduction with dulaglutide (1.5 mg). 

Semaglutide weight loss results are even better at Wegovy®’s higher doses. The STEP UP trial compared Wegovy®’s 2.4 mg and 7.2 mg doses head-to-head. Participants on the 7.2 mg dose lost an average of 20.7% of their body weight over 72 weeks, compared to 17.5% on the 3.4 mg dose. 

But weight loss with either medication requires ongoing treatment. In the STEP 1 extension study, researchers followed participants for one year after they stopped semaglutide. On average, they regained two-thirds of the weight they had lost, and improvements in cholesterol and blood sugar reverted toward baseline.

Outcomes also depend on tolerability. Wegovy®’s higher dose comes with higher rates of side effects in the digestive system, which can make it harder for some people to reach or stay on the maintenance dose. Follow-up with a provider to adjust dosing, manage side effects, and build sustainable habits around nutrition and movement can make a real difference in whether the medication works long term.

‍

‍

‍

Which has more side effects, Trulicity® or Wegovy®?

Both medications cause similar side effects, mostly in the digestive system. But people taking Wegovy® experience them more often because the drug delivers a higher dose of a longer-acting molecule. At their standard maintenance doses, digestive system-related side effects showed up in 41% of Trulicity® patients versus 73% of Wegovy® patients in clinical trials.

Here’s how the most common side effects compare:

‍

Getting the full benefit of either medication also heavily depends on side effect management. Maven Clinic’s GLP-1 Care program connects you directly with specialists who can step in early, adjusting your dose to minimize these experiences.

‍

Trulicity® vs. Wegovy®: Cost and insurance coverage

The most effective medication is the one you can stay on. And for many people, cost and coverage shape that decision as much as clinical fit. 

Both Trulicity® and Wegovy® are branded drugs without generic alternatives, and their list prices can surpass $1,000 per month without insurance. But what you actually pay depends on what the drug is approved for, what your insurance plan covers, and whether your provider completes the documentation your insurer requires.

Trulicity® has a coverage advantage here. Because it’s FDA-approved for type 2 diabetes, a condition most commercial plans and Medicare Part D cover broadly, patients with a diabetes diagnosis generally face fewer access barriers. 

The path to get Wegovy® treatment covered by insurance is less straightforward. About 40–50% of large employer plans cover anti-obesity medications, but coverage is expanding unevenly. Medicare is also trialing a GLP-1 Bridge program, which reduces the cost of the medication to a $50 copay. However, this is limited to eligible patients who apply during a set timeline.

Even with coverage, people may run into additional barriers:

• Prior authorization: Both drugs may require it, but it’s more common for Wegovy®, particularly when prescribed for weight management.
• Step therapy: Some plans require patients to try lifestyle interventions or older medications before approving a GLP-1.
• Supply constraints: Wegovy® has appeared on the FDA drug shortage list in recent years, which can delay or interrupt treatment.

‍

How to choose between Trulicity® and Wegovy® and create a plan for you

The right choice between these two depends on your primary health goal, medical history, and insurance coverage. No comparison article can replace a conversation with a provider who understands how to work with all these factors.

Maven Clinic’s GLP-1 Care program starts with that conversation. The program pairs you with a care team that seeks to understand the whole picture and stays with you through dosing, side effects, and the habits that build sustainable results. Learn more and start your journey today.

‍